Overview
- A Cleveland Clinic analysis of more than 10,000 patients reported on May 22, 2026 that people who started GLP-1 receptor agonists after an early-stage cancer diagnosis had lower rates of progression to metastatic disease.
- The study found statistically significant reductions in progression for non-small cell lung, breast, colorectal and liver cancers with the largest effects in lung and breast tumors.
- All results come from retrospective database comparisons that matched GLP-1 users to patients starting DPP-4 inhibitors and cannot prove the drugs caused the benefit because of possible residual confounding.
- Investigators and outside experts offer multiple hypotheses for the signal, including effects on tumor GLP-1 receptors, changed tumor metabolism, reduced inflammation and weight loss, but the mechanism remains unproven.
- Authors will present findings at ASCO and say the drugs appear safe for patients who need them for diabetes or weight management while calling for randomized clinical trials and mechanistic research before changing cancer care.